Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.

Abstract: The present invention provides cultured leukemia cells. The method comprises isolating mononuclear cells, which contain leukemia cells, culturing the leukemia cells in a chamber having a scaffolding covered or surrounded with culture medium, where the scaffolding allows for leukemia cells to have cell to cell contacts in three dimensions. The subject leukemia cells are useful for screening compounds which inhibit or stimulate leukemia cell function or formation.

Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.

Abstract: The present invention relates to isolated nucleic acid molecules encoding splice variants LATS2b and LATS2c, isolated LATS2b and LATS2c protein or polypeptides, and antibodies to the LATS2b and LATS2c proteins or polypeptides. The present invention also relates to methods of using the LATS2b and LATS2c nucleic acid molecules and proteins or polypeptides, including for detecting the expression of LATS2b or LATS2c in a biological sample, regulating LATS2b or LATS2c expression, screening drugs that regulate LATS2b or LATS2c activity and expression, regulating cell growth and differentiation, and treating disease conditions in a subject. Also disclosed are expression vectors, host cells, and transgenic animals transformed with LATS2b and LATS2c nucleic acid molecules.

Abstract: The present invention relates to an isolated nucleic acid molecule encoding an IWU-1 protein or polypeptide; an isolated IWU-1 protein or polypeptide encoded by the nucleic acid molecule of the present invention; an isolated antibody against the protein or polypeptide encoded by the nucleic acid molecule; and uses for the nucleic acid molecule, the protein, and its antibody, including in the making of a vaccine, and in various in methods, including for detection of IWU-1 in a biological sample; treating a disease condition in a subject; regulating IWU-1 expression in a subject, and in methods of screening drugs that regulate IWU-1 expression. Also disclosed are vectors, host cells, and transgenic animals having the nucleic acid molecule encoding an IWU-1 protein or polypeptide of the present invention.

Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.

Abstract: Methods of controlling bone marrow cell development, stem cell self-renewal, differentiation and/or function, and expression of clock controlled genes having an E-box sequence in their regulatory region by providing appropriate cells having a circadian clock system and manipulating the circadian clock system under conditions effective to control bone marrow cell development, stem cell self-renewal, differentiation and/or function, as well as expression of clock controlled genes having an E-box sequence in their regulatory region. In addition, an in vitro engineered tissue is disclosed that includes a plurality of cells or cell types in intimate contact with one another to form a tissue, the cells or cell types having a circadian clock system that has been modulated to regulate growth, development and/or functions of the cells or cell types within the tissue.

Abstract: The present invention provides cultured immune system cells and methods of producing same. The method comprises culturing stromal cells and hemopoietic stem cells or in a chamber having a scaffolding covered or surrounded with culture medium, wherein the scaffolding allows for hemopoietic stem cells and stromal cells to have cell to cell contacts in three dimensions. The subject immune system cells are useful for screening drugs which inhibit or stimulate the immune system. The subject immune system cells are also useful in treating diseases of the immune system.

Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.

Abstract: The present invention provides cultured leukemia cells. The method comprises isolating mononuclear cells, which contain leukemia cells, culturing the leukemia cells in a chamber having a scaffolding covered or surrounded with culture medium, where the scaffolding allows for leukemia cells to have cell to cell contacts in three dimensions. The subject leukemia cells are useful for screening compounds which inhibit or stimulate leukemia cell function or formation.